All patients (n = 13) | |
---|---|
Age, mean (SD), years; (min-max) | 48.23 ± 14.5, (21–67) |
Female, n (%) | 9 (69.2%) |
Disease duration, mean (SD), years; (min-max) | 11.46 ± 9.44; (2–36) |
TCZ exposure before tapering, months (SD); (min-max) | 18.38 ± 7.34; (5–29) |
Remission achievement delay, months (SD); (min-max) | 2.38 ± 2.63; (0–8) |
Remission duration, months (SD); (min-max) | 7.53 ± 6.21; (3–24) |
RF positive, n (%) | 7 (53.8%) |
ACPA positive, n (%) | 7 (53.8%) |
Erosive status, n (%) | 10 (76.9%) |
Previous number of sDMARDs; (min-max) | 2.15 ± 0.9; (1–4) |
Previous number of bDMARDs; (min-max) | 1.7 ± 1.18; (0–3) |
Swollen joint count; (min-max) | 0.08 ± 0.27; (0–1) |
Tender joint count; (min-max) | 3.14 ± 3.4; (0–10) |
Hyperhemia at Doppler | 2 (15.4%) |
Number of patients with active synovitis | 7 (53.8%) |
Number of active synovitis | |
Hands | 14 |
Feet | 5 |
Concomitant therapy | |
MTX, n (%) | 6 (42.9%) |
LEF, n (%) | 3 (21.4%) |
DAS28; mean (SD); (min-max) | 1.65 ± 0.93; (0–2.6) |
ESR, mm/h; mean (SD); (min-max) | 7 ± 9.12; (1–27) |
CRP, mg/L, mean (SD); (min-max) | 2.21 ± 2.34; (0.2–7.4) |
TCZ plasma level, mg/L; mean (SD); (min-max) | 7.35 ± 6.41; (0–16) |
ADAb positivity | 0 |